Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced one late- breaker oral platform presentation and two poster presentations to be presented at the International Congress of Parkinson's Disease and Movement Disorders® being held October 5-9, 2025, in Honolulu, Hawaii. The presentations highlight updates from the company's robust pipeline including preclinical efficacy, safety and mechanism of action findings on Acadia's investigational drug ACP-711, under deve. ...